Feedback / Questions
elritercept (KER-050) - Takeda
Elritercept: Regulatory filing for 2L anemia-associated MDS in FY2027-FY2029
(Takeda)
-
Jan 30, 2026 -
Q3 FY2025 Results
Filing
•
Hematological Malignancies • Myelodysplastic Syndrome • Oncology
https://assets-dam.takeda.com/image/upload/v1769652878/Global/Investor/Financial-Results/FY2025/Q3/qr2025_q3_p01_en.pdf
Jan 30, 2026
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious